Alnylam Pharmaceuticals | ALNY - Cash And Equivalent

Stock Price
318.85
Daily Change
-9.88 -3.01%
Monthly
0.06%
Yearly
21.62%
Q2 Forecast
307.84

Alnylam Pharmaceuticals reported $1.66B in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 819.69M 27.33M Dec/2025
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Amgen USD 9.13B 316M Dec/2025
Arrowhead Research USD 201.64M 112.94M Dec/2025
BioCryst Pharmaceuticals USD 335.91M 251.83M Dec/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Incyte USD 3.58B 650.78M Dec/2025
Ionis Pharmaceuticals USD 2.68B 437M Dec/2025
Moderna USD 2.6B 1.46B Dec/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
Takeda JPY 654.94B 26.55B Dec/2025
Tectonic Therapeutic USD 253.8M 14.64M Dec/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025
Xencor USD 54.07M 25.78M Dec/2025